Transarterial Chemoembolization Market Report: Trends, Forecast and Competitive Analysis to 2030
Transarterial Chemoembolization Trends and Forecast
The future of the global transarterial chemoembolization market looks promising with opportunities in the hospital, clinic, and cancer research center markets. The global transarterial chemoembolization market is expected to reach an estimated $24.1 billion by 2030 with a CAGR of 5.7% from 2024 to 2030. The major drivers for this market are increasing incidence of liver cancer, continuous advancements in TACE techniques and technology, and growing demand for minimally invasive cancer treatments.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Transarterial Chemoembolization by Segment
The study includes a forecast for the global transarterial chemoembolization by product type, procedure type, indication, end use, and region.
Transarterial Chemoembolization Market by Product Type
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies transarterial chemoembolization companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the transarterial chemoembolization companies profiled in this report include-
Lucintel forecasts that drug-eluting particle is expected to witness highest growth over the forecast period.
Within this market, hospital is expected to witness highest growth over the forecast period.
North America is expected to witness highest growth over the forecast period.
Features of the Global Transarterial Chemoembolization Market
Market Size Estimates: Transarterial chemoembolization market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Transarterial chemoembolization market size by various segments, such as by product type, procedure type, indication, end use, and region in terms of value ($B).
Regional Analysis: Transarterial chemoembolization market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product type, procedure types, indications, end uses, and regions for the transarterial chemoembolization market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the transarterial chemoembolization market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the transarterial chemoembolization market size?
Answer: The global transarterial chemoembolization market is expected to reach an estimated $24.1 billion by 2030.
Q2. What is the growth forecast for transarterial chemoembolization market?
Answer: The global transarterial chemoembolization market is expected to grow with a CAGR of 5.7% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the transarterial chemoembolization market?
Answer: The major drivers for this market are increasing incidence of liver cancer, continuous advancements in tace techniques and technology, and growing demand for minimally invasive cancer treatments.
Q4. What are the major segments for transarterial chemoembolization market?
Answer: The future of the transarterial chemoembolization market looks promising with opportunities in the hospital, clinic, and cancer research center markets.
Q5. Who are the key transarterial chemoembolization market companies?
Answer: Some of the key transarterial chemoembolization companies are as follows:
Answer: Lucintel forecasts that drug-eluting particle is expected to witness highest growth over the forecast period.
Q7. In transarterial chemoembolization market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the transarterial chemoembolization market by product type (chemotherapeutic agents, radio therapeutic agents, and drug-eluting particles), procedure type (conventional TACE and DEB-TACE), indication (unresectable HCC and early-stage HCC), end use (hospitals, clinics, cancer research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Transarterial Chemoembolization Market, Transarterial Chemoembolization Market Size, Transarterial Chemoembolization Market Growth, Transarterial Chemoembolization Market Analysis, Transarterial Chemoembolization Market Report, Transarterial Chemoembolization Market Share, Transarterial Chemoembolization Market Trends, Transarterial Chemoembolization Market Forecast, Transarterial Chemoembolization Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
The future of the global transarterial chemoembolization market looks promising with opportunities in the hospital, clinic, and cancer research center markets. The global transarterial chemoembolization market is expected to reach an estimated $24.1 billion by 2030 with a CAGR of 5.7% from 2024 to 2030. The major drivers for this market are increasing incidence of liver cancer, continuous advancements in TACE techniques and technology, and growing demand for minimally invasive cancer treatments.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Transarterial Chemoembolization by Segment
The study includes a forecast for the global transarterial chemoembolization by product type, procedure type, indication, end use, and region.
Transarterial Chemoembolization Market by Product Type
- Chemotherapeutic Agents
- Radio Therapeutic Agents
- Drug-Eluting Particles
- Conventional TACE
- DEB-TACE
- Unresectable HCC
- Early-Stage HCC
- Hospitals
- Clinics
- Cancer Research Centers
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies transarterial chemoembolization companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the transarterial chemoembolization companies profiled in this report include-
- Novartis
- Nippon Kayaku
- Pfizer
- Spectrum Pharmaceuticals
- CELGENE
- Siemens Healthcare
- Bayer
- Merck
- Cook
- F. Hoffmann-La Roche
Lucintel forecasts that drug-eluting particle is expected to witness highest growth over the forecast period.
Within this market, hospital is expected to witness highest growth over the forecast period.
North America is expected to witness highest growth over the forecast period.
Features of the Global Transarterial Chemoembolization Market
Market Size Estimates: Transarterial chemoembolization market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Transarterial chemoembolization market size by various segments, such as by product type, procedure type, indication, end use, and region in terms of value ($B).
Regional Analysis: Transarterial chemoembolization market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product type, procedure types, indications, end uses, and regions for the transarterial chemoembolization market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the transarterial chemoembolization market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the transarterial chemoembolization market size?
Answer: The global transarterial chemoembolization market is expected to reach an estimated $24.1 billion by 2030.
Q2. What is the growth forecast for transarterial chemoembolization market?
Answer: The global transarterial chemoembolization market is expected to grow with a CAGR of 5.7% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the transarterial chemoembolization market?
Answer: The major drivers for this market are increasing incidence of liver cancer, continuous advancements in tace techniques and technology, and growing demand for minimally invasive cancer treatments.
Q4. What are the major segments for transarterial chemoembolization market?
Answer: The future of the transarterial chemoembolization market looks promising with opportunities in the hospital, clinic, and cancer research center markets.
Q5. Who are the key transarterial chemoembolization market companies?
Answer: Some of the key transarterial chemoembolization companies are as follows:
- Novartis
- Nippon Kayaku
- Pfizer
- Spectrum Pharmaceuticals
- CELGENE
- Siemens Healthcare
- Bayer
- Merck
- Cook
- F. Hoffmann-La Roche
Answer: Lucintel forecasts that drug-eluting particle is expected to witness highest growth over the forecast period.
Q7. In transarterial chemoembolization market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the transarterial chemoembolization market by product type (chemotherapeutic agents, radio therapeutic agents, and drug-eluting particles), procedure type (conventional TACE and DEB-TACE), indication (unresectable HCC and early-stage HCC), end use (hospitals, clinics, cancer research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Transarterial Chemoembolization Market, Transarterial Chemoembolization Market Size, Transarterial Chemoembolization Market Growth, Transarterial Chemoembolization Market Analysis, Transarterial Chemoembolization Market Report, Transarterial Chemoembolization Market Share, Transarterial Chemoembolization Market Trends, Transarterial Chemoembolization Market Forecast, Transarterial Chemoembolization Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Transarterial Chemoembolization Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Transarterial Chemoembolization Market by Product Type
3.3.1: Chemotherapeutic Agents
3.3.2: Radio Therapeutic Agents
3.3.3: Drug-Eluting Particles
3.4: Global Transarterial Chemoembolization Market by Procedure Type
3.4.1: Conventional TACE
3.4.2: DEB-TACE
3.5: Global Transarterial Chemoembolization Market by Indication
3.5.1: Unresectable HCC
3.5.2: Early-Stage HCC
3.6: Global Transarterial Chemoembolization Market by End Use
3.6.1: Hospitals
3.6.2: Clinics
3.6.3: Cancer Research Centers
3.6.4: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Transarterial Chemoembolization Market by Region
4.2: North American Transarterial Chemoembolization Market
4.2.1:North American Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.2.2: North American Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
4.3: European Transarterial Chemoembolization Market
4.3.1: European Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.3.2: European Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
4.4: APAC Transarterial Chemoembolization Market
4.4.1: APAC Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.4.2: APAC Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
4.5: ROW Transarterial Chemoembolization Market
4.5.1: ROW Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.5.2: ROW Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Transarterial Chemoembolization Market by Product Type
6.1.2: Growth Opportunities for the Global Transarterial Chemoembolization Market by Procedure Type
6.1.3: Growth Opportunities for the Global Transarterial Chemoembolization Market by Indication
6.1.4: Growth Opportunities for the Global Transarterial Chemoembolization Market by End Use
6.1.5: Growth Opportunities for the Global Transarterial Chemoembolization Market by Region
6.2: Emerging Trends in the Global Transarterial Chemoembolization Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Transarterial Chemoembolization Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Transarterial Chemoembolization Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Novartis
7.2: Nippon Kayaku
7.3: Pfizer
7.4: Spectrum Pharmaceuticals
7.5: CELGENE
7.6: Siemens Healthcare
7.7: Bayer
7.8: Merck
7.9: Cook
7.10: F. Hoffmann-La Roche
2. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Transarterial Chemoembolization Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Transarterial Chemoembolization Market by Product Type
3.3.1: Chemotherapeutic Agents
3.3.2: Radio Therapeutic Agents
3.3.3: Drug-Eluting Particles
3.4: Global Transarterial Chemoembolization Market by Procedure Type
3.4.1: Conventional TACE
3.4.2: DEB-TACE
3.5: Global Transarterial Chemoembolization Market by Indication
3.5.1: Unresectable HCC
3.5.2: Early-Stage HCC
3.6: Global Transarterial Chemoembolization Market by End Use
3.6.1: Hospitals
3.6.2: Clinics
3.6.3: Cancer Research Centers
3.6.4: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Transarterial Chemoembolization Market by Region
4.2: North American Transarterial Chemoembolization Market
4.2.1:North American Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.2.2: North American Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
4.3: European Transarterial Chemoembolization Market
4.3.1: European Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.3.2: European Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
4.4: APAC Transarterial Chemoembolization Market
4.4.1: APAC Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.4.2: APAC Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
4.5: ROW Transarterial Chemoembolization Market
4.5.1: ROW Transarterial Chemoembolization Market by Product Type: Chemotherapeutic Agents, Radio Therapeutic Agents, and Drug-Eluting Particles
4.5.2: ROW Transarterial Chemoembolization Market by End Use: Hospitals, Clinics, Cancer Research Centers, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Transarterial Chemoembolization Market by Product Type
6.1.2: Growth Opportunities for the Global Transarterial Chemoembolization Market by Procedure Type
6.1.3: Growth Opportunities for the Global Transarterial Chemoembolization Market by Indication
6.1.4: Growth Opportunities for the Global Transarterial Chemoembolization Market by End Use
6.1.5: Growth Opportunities for the Global Transarterial Chemoembolization Market by Region
6.2: Emerging Trends in the Global Transarterial Chemoembolization Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Transarterial Chemoembolization Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Transarterial Chemoembolization Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Novartis
7.2: Nippon Kayaku
7.3: Pfizer
7.4: Spectrum Pharmaceuticals
7.5: CELGENE
7.6: Siemens Healthcare
7.7: Bayer
7.8: Merck
7.9: Cook
7.10: F. Hoffmann-La Roche
